| Patient | Wilma Mankiller |
|---|---|
| Date of birth | 1991-11-18 |
| Identifiers | MRN HR-ML052-SYN; SSN (made up) 000-52-4183 |
| Document date | 2026-10-12 |
| Author | Rena Hawkfeather-Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-month review. [S]
Ms. Mankiller returns seven months after her diagnosis. She has had no drooping eyelids, double vision or trouble chewing since the summer; only after a very long day does she feel her arms tire. Prednisone is now 15 mg each morning, and she stopped trimethoprim-sulfamethoxazole when the dose fell below 20 mg last week, as planned. She takes azathioprine 150 mg daily; the blood tests at the Cherokee Nation clinic two and six weeks after the dose increase were normal and the nurse called her each time. She has returned to full-time work. She sleeps better on the lower prednisone dose. Home blood pressure readings average 116/74. She drinks about 2.5 liters of water a day and has had no flank pain or blood in the urine. She would like fewer pyridostigmine tablets. [S]
| Element | Detail |
|---|---|
| Strength | MG-ADL 1: minimal manifestation status |
| Medicines | Prednisone 15 mg; azathioprine 150 mg; pyridostigmine 60 mg four times daily; trimethoprim-sulfamethoxazole stopped |
| Work | Full time |
| Kidneys | Home blood pressure about 116/74; no symptoms |
| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No ptosis or double vision |
| Musculoskeletal | Positive | Arms tire only after very long days |
| Genitourinary | Negative | No flank pain or blood in the urine |
| Constitutional | Negative | No fever or infections; weight down 1 kg |
| Psychiatric | Negative | Mood good; sleeping better; PHQ-2 score 0 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 2026-03-09 to 2026-03-23 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals | One tablet four times daily while awake | Oral route | 2026-03-23 to 2026-10-12 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet three times daily, 30 to 45 minutes before meals | One tablet three times daily | Oral route | 2026-10-12 | active | S |
| Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg | Once each morning; dose as directed | Oral route | 2026-03-23 to 2026-07-13 | completed | S |
| Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeks | Once each morning; dose as directed | Oral route | 2026-07-13 | active | S |
| Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily | Once daily; dose as directed | Oral route | 2026-05-04 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food | One tablet daily with food | Oral route | 2026-03-23 | active | S |
| Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine | One tablet on Monday, Wednesday and Friday | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 2025-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-12 | Body height | 163 | cm | S |
| 2026-10-12 | Body weight | 63.6 | kg | S |
| 2026-10-12 | Body mass index (BMI) [Ratio] | 23.9 | kg/m2 | S |
| 2026-10-12 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-10-12 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-12 | Heart rate | 72 | /min | S |
| 2026-10-12 | Respiratory rate | 14 | /min | S |
| 2026-10-12 | Body temperature | 36.6 | Cel | S |
| 2026-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-12 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-10-12 | Leukocytes [#/volume] in Blood by Automated count | 5.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-12 | Platelets [#/volume] in Blood by Automated count | 238 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 99 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 7-45 U/L | Normal | S |
| 2026-10-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.6 | % | <=5.6% | Normal | S |
| 2026-10-12 | Albumin/Creatinine [Mass Ratio] in Urine | 16 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-10-12 | Forced vital capacity [Volume] Respiratory system | 3.62 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-10-12 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-10-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 118/76 mm Hg; weight 63.6 kg |
| Eyes | No ptosis after one minute of upgaze; no diplopia |
| Neurological | Strength 5 of 5 without fatigue; speech normal |
| Abdomen | Both kidneys palpable, non-tender |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | resolved | confirmed | H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980 | active | confirmed | G70.00 | S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D). |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
| Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infection | active | confirmed | Z79.52 | S — Synthetic treatment plan. |
| Azathioprine as steroid-sparing therapy, with blood count and liver test monitoring | active | confirmed | Z79.624 | S — Synthetic treatment plan. |
| Acquired absence of the thymus after robotic extended thymectomy for myasthenia gravis (pathology: thymic follicular hyperplasia, no thymoma) | active | confirmed | Z90.89 | S — Synthetic: recorded after the thymectomy; the sources name surgery among her treatments without saying which. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | MG-ADL score and post-intervention status | Every visit | Completed today | 1; minimal manifestation status |
| Imaging | Forced vital capacity | Every visit while on dose changes | Completed today | 3.62 L |
| Laboratory | Blood count on azathioprine | Every three months after the first two months | Completed today | Hemoglobin 12.9 g/dL; white cells 5.4; platelets 238 |
| Laboratory | Liver tests and creatinine on azathioprine | Every three months | Completed today | ALT 23 U/L; creatinine 0.80 mg/dL; eGFR 99 |
| Laboratory | Hemoglobin A1c on glucocorticoids | Periodically | Completed today | 5.6 percent |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly in ADPKD | Completed today | 16 mg/g |
| Examination | Blood pressure | Every visit | Completed today | 118/76 mm Hg in clinic; home average 116/74 |
| Imaging | Bone density (DXA) | Every one to three years on glucocorticoids by risk | Up to date | Normal five months ago; repeat if glucocorticoids continue beyond a year |
| Examination | Eye examination on glucocorticoids | Yearly | Ordered | Booked next month at the Cherokee Nation eye clinic |
| Medication safety | Pneumocystis prophylaxis | While prednisone is 20 mg or more with azathioprine | Not indicated | Stopped last week when prednisone fell below 20 mg |
| Medication safety | Medicines that can worsen myasthenia gravis | With every new prescription | Completed today | None prescribed; the list reviewed |
| Medication safety | Vaccines on immunosuppression | Seasonal | Completed today | Inactivated influenza and COVID-19 vaccines today |
| Survey | Depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 0 |
| Self-management | Water intake, salt, home blood pressure and laboratory access | Every visit | Completed today | About 2.5 liters a day; home readings monthly; standing orders at the Cherokee Nation clinic working |
Goal progress:
Immunizations given today: Inactivated influenza vaccine, this season; COVID-19 vaccine, mRNA, this season [S]
Guideline basis: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022)
Follow-up: Blood count and liver tests every three months at the Cherokee Nation clinic. Eye examination next month. Neuromuscular neurology in three months. Review here in three months. [S]